Jetbio rolls out miniReJI 3D Bioprinters for printing of cancer cell models

Jetbio rolls-out its miniReJI 3D bioprinter in the UK for faster, accurate and more efficient pharmaceutical drug discovery

Researchers produce cancer cell models more rapidly and closely mimicking human tissue.

We all rely on therapeutic pharmaceutical drugs for good healthcare.  Pharmaceutical companies spend $billions on researching new drugs that can take over 10 years to reach regulatory approvals, and only about 10% make it that far.  More predictive clinical models will enable a more efficient process and over a shorter development time.

In its recent announcement, the FDA has confirmed that it will not require new therapeutics to be tested on animals if manufacturers can demonstrated that pre-clinical data is accurate and reproducible.

Jetbio 3D bioprinters and bioinks are designed to have significant positive impact on the drug discovery process by rapidly printing and delivering more accurate 3D printed models that closely mimic human tissue for the pre-clinical testing of new drug components.  The company’s new micro-valve inkjet 3D Bioprinters are no bigger than a desktop computer, easily portable and supplied with user-friendly software. 

The Jetbio technology will also support applications in tissue engineering, for example in-clinic processing of 3D tissue constructs for regenerative implants.

Jetbio Chief Executive Dennis Camilleri says “We have reached significant milestones by designing robust, scalable products for manufacture and first installations at User sites in the UK. The company’s mission is to build a global business and to become the supplier of choice for 3D bioprinting systems".

Jetbio Chief Scientific Officer and Professor of Manufacturing Engineering, Kenny Dalgarno says “The technology is covered by granted patents in Europe and the USA and is underpinned by over 5 years of research at Newcastle University. With partners we’ve demonstrated that we can print cells to build models of osteoarthritis, leukaemia, and cardiac conditions, with potential for creating 3D cell culture models for many more applications.”